How to Switch from Tirzepatide to Retatrutide

Most researchers who switch from tirzepatide to retatrutide do it because tirzepatide stopped moving the scale, not because retatrutide is officially better. The common approach is simple: take the last tirzepatide dose, wait about 7 to 14 days, then start retatrutide low, usually around the 2 mg trial starting dose.

There is no head-to-head switching trial in humans. The numbers below are pulled from primary sources: the FDA labels for Mounjaro and Zepbound (both tirzepatide), the New England Journal of Medicine Phase 2 retatrutide paper, and the December 2025 TRIUMPH-4 Phase 3 readout. Those details come from trial dose ladders, not from a study that followed people switching from tirzepatide to retatrutide. That gap matters and is called out in the body.

The most common reason is a tirzepatide plateau. Someone has been on tirzepatide for 6 to 12 months, dose has climbed to the upper end of what they tolerate, the scale has stopped moving for a month or more, and they want to know if retatrutide can break through.

The logic is pretty simple. Tirzepatide is a dual agonist: it activates GLP-1 and GIP receptors. Retatrutide is a triple agonist: it activates GLP-1, GIP, and glucagon receptors. The glucagon receptor is the one tirzepatide does not hit. In trials, the added glucagon activity is linked to higher energy expenditure on top of appetite suppression. That is why some researchers see retatrutide as a possible plateau breaker.

Trial results support the idea that retatrutide may have a higher ceiling, but they do not answer the switching question directly. In the SURMOUNT-1 obesity trial, tirzepatide produced mean body weight reduction in the low 20s percent over 72 weeks. In the retatrutide Phase 2 NEJM trial, the 12 mg dose produced 24.2% mean weight reduction at 48 weeks. In TRIUMPH-4, reported on December 11, 2025, the 12 mg dose produced 28.7% mean weight reduction at 68 weeks. Different trial populations, different durations, no direct switching arm, but the ceiling looks higher with retatrutide.

The washout question really comes down to two numbers: tirzepatide's half-life of about 5 days from the Mounjaro and Zepbound FDA labels, and retatrutide's half-life of about 6 days from the NEJM Phase 2 paper.

Half-life is the time it takes for the blood level of a drug to fall by half. After one half-life, about 50% of a dose is left. After two, about 25%. After four to five, the drug is considered effectively cleared. For tirzepatide at a 5-day half-life, full clearance takes roughly 4 to 5 weeks after the last dose.

Those half-life numbers explain the three switch patterns researchers usually discuss. A 7-day washout means starting retatrutide with tirzepatide still at roughly 50% of its last-dose level. A 14-day washout means starting at about 25%. A 21-day washout means starting at about 12.5%. None of these are right or wrong on their own; each is a trade-off between clean baseline and how long appetite returns before retatrutide takes hold.

The three patterns below are what the research community has converged on. None of them are from a published switching trial. They are research-community protocols based on half-life timing, not medical recommendations.

Take the last tirzepatide dose on the normal weekly day. Wait 7 days. Then take the first retatrutide dose at 2 mg. This is the option most competitor protocols and community write-ups describe as the default.

Same idea, longer pause. Take the last tirzepatide dose, wait 14 to 21 days, then start retatrutide at 2 mg. After 14 days about 75% of the last tirzepatide dose is gone. After 21 days about 87.5% is gone.

Skip the washout. Take retatrutide on what would have been the next tirzepatide injection day. This is the highest-risk approach for side-effect stacking because tirzepatide is still at about 100% of steady-state when retatrutide goes in.

The most common research-community pattern, and the one used in the retatrutide Phase 2 NEJM trial, is to start at 2 mg per week regardless of where tirzepatide ended. Even researchers ending tirzepatide at 12.5 mg or 15 mg typically begin retatrutide at 2 mg.

The reason is the glucagon receptor. Tirzepatide tolerance carries over only on the shared GLP-1 and GIP pathways. The glucagon receptor is the new variable, and the trial protocols built a slow ramp specifically to let the body adapt to glucagon activation. Skipping that ramp is the most reported cause of severe nausea in the first few weeks of retatrutide.

Many researchers say the first 4 to 6 weeks feel slower than expected. Appetite returns during the washout, the first retatrutide dose is sub-therapeutic on purpose, and the visible payoff usually shows up between weeks 5 and 8 once the dose climbs into the 4 mg range or higher.

Most competitors only cover one direction. In practice, some researchers switch back. Common reasons are retatrutide cost or supply pressure, side effects that did not settle, or a preference for tirzepatide's better-established long-term safety profile (tirzepatide is FDA-approved as Mounjaro and Zepbound; retatrutide is still investigational).

The reverse switch uses the same half-life logic. Take the last retatrutide dose, wait 7 to 14 days, then start tirzepatide at a moderate dose. Most researchers do not return straight to their old top tirzepatide dose. A common pattern is to step back in at 5 mg or 7.5 mg and re-titrate, which is consistent with how the Mounjaro and Zepbound FDA labels structure the titration ladder for re-starts.

As of May 2026, tirzepatide is FDA-approved as Mounjaro for type 2 diabetes (initial U.S. approval 2022) and as Zepbound for chronic weight management. Retatrutide is investigational, not FDA-approved, and is only legally available through clinical trial enrollment or research-use-only suppliers.

TRIUMPH-4, reported on December 11, 2025, was the first successful Phase 3 readout for retatrutide. Seven additional Phase 3 trials are expected to report results throughout 2026. NDA submission to the U.S. FDA is projected for late 2026 or early 2027, with potential approval in late 2027. None of these dates are confirmed by the FDA or Eli Lilly — they are projections from public trial timelines.

Anyone planning a switch needs both compounds on hand: a final tirzepatide vial to finish the last dose, and a retatrutide vial ready for the first dose after the washout. Running out mid-transition is avoidable and can throw off the whole plan.

For the full sourcing breakdown — Finnrick data, supplier ratings, and red/green flag checklist — read How to get retatrutide in 2026. For dose math during the transition, use the PepPal calculator. For protocol-level dosing structure, use the retatrutide protocol on Peptide Dosing Protocols.